2303-PUB: Efficacy of Dulaglutide (DU) as First Injectable Option for Patients with Type 2 Diabetes (T2D): A Post Hoc Pooled Analysis

Background: ADA-EASD consensus report recommends using GLP-1RAs including DU as 1st injectable therapy prior to basal insulin in most patients with T2D not at their glycemic goals after oral antidiabetic medications (OADs). Objective To assess the glycemic efficacy of DU 1.5 mg in patients with T2D when added on background of commonly used OAD regimens. Methods: Patients from 7 Phase-3 trials where DU 1.5 mg was added to OADs were pooled and...